Susana W. Keeshin
( out of 18 reviews )

Susana W. Keeshin, MD

Languages spoken: English, Spanish

Dr. Keeshin received her medical degree from Meharry Medical College, completed her Internal Medicine and Pediatric Residency at the University of Utah and her Infectious Disease Fellowship at the University of Cincinnati. She is currently an Associate Professor in the Division of Pediatric Infectious Disease at the University of Utah and Primary Children’s Hospital. She cares for adult HIV patients at Intermountain Health IMC Infectious Disease in Murray and pediatric patients at Primary Children’s Hospital. Dr. Keeshin’s clinical interests include medical care of people living or affected by HIV, transitioning HIV infected youth into adult health care, treatment of HIV/HCV coinfection, HIV pre-exposure prophylaxis (PreP) and general infectious diseases.

Specialties

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine (Sub: Infectious Disease)

Patient Rating

4.8 /5
( out of 18 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Dr. Keeshin received her medical degree from Meharry Medical College, completed her Internal Medicine and Pediatric Residency at the University of Utah and her Infectious Disease Fellowship at the University of Cincinnati. She is currently an Associate Professor in the Division of Pediatric Infectious Disease at the University of Utah and Primary Children’s Hospital. She cares for adult HIV patients at Intermountain Health IMC Infectious Disease in Murray and pediatric patients at Primary Children’s Hospital. Dr. Keeshin’s clinical interests include medical care of people living or affected by HIV, transitioning HIV infected youth into adult health care, treatment of HIV/HCV coinfection, HIV pre-exposure prophylaxis (PreP) and general infectious diseases.

Board Certification and Academic Information

Academic Departments Pediatrics -Associate Professor (Clinical)
Academic Divisions Infectious Diseases
Board Certification
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Infectious Disease)

Education history

Fellowship Infectious Disease - University of Cincinnati Fellow
Internship/Residency Internal Medicine and Pediatrics - University of Utah Intern/Resident
Professional Medical Medicine - Meharry Medical College M.D.
Undergraduate Sociology - University of Utah B.A.
Undergraduate Spanish Literature - University of Utah B.A.
Undergraduate Biology - University of Utah B.S.

Selected Publications

Journal Article

  1. Colson AE, Kumar PN, Ruane PJ, Chetchotisakd P, Ratanasuwan W, Liberty A, Nahass RG, Arenas-Pinto A, Post FA, Baker DA, Cahn P, Hofmann E, Watanabe D, Lu PL, Roukens AHE, Parczewski M, Wang H, Chen K, Shihadeh F, Shaughnessy M, Dvory-Sobol H, SenGupta D, Llamoso C, Rhee M, Ogbuagu O, ISLEND-2 Study Team (2026). Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial. Lancet, 408(10557), 821-832.
  2. Meissner EG, Ramgopal M, Ruane PJ, Sanchez W, Crofoot G, Routy JP, Brinson C, DeJesus E, Martorell CT, Tellez M, Yokomaku Y, OReilly M, Lupo S, Schellberg S, Lezama-Mora JI, Chin B, Aizen K, DAntoni ML, Huang H, Mponponsuo K, Montezuma-Rusca JM, Sklar P, Rhee M, Hung CC, ARTISTRY-2 Study Group (2026). Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV, 13(8), e538-e547.
  3. Hatch MA, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K, Tross S (2025). HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here? Curr HIV/AIDS Rep, 22(1), 13.
  4. Strawn JR, Mills JA, Schroeder HK, Neptune ZA, Specht A, Keeshin SW (2023). The Impact of COVID-19 Infection and Characterization of Long COVID in Adolescents With Anxiety Disorders: A Prospective Longitudinal Study. J Am Acad Child Adolesc Psychiatry, 62(7), 707-709.
  5. Person AK, Armstrong WS, Evans T, Fangman JJW, Goldstein RH, Haddad M, Jain MK, Keeshin S, Tookes HE, Weddle AL, Feinberg J (2022). Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medical Association. Clin Infect Dis, 76(1), 1-9.
  6. Feinberg J, Keeshin S (2022). Prevention and Initial Management of HIV Infection. Ann Intern Med, 175(12), W152.
  7. McLean S, Westerdahl SJ, Lu SM, Knecht RA, Spivak AM, Keeshin SW (2021). Patient Exposure through a Free Prophylaxis (PrEP) Clinic Improves Medical Student Comfort with Sexual Health and LGBTQIA+ Topics. AMA Research Symposium 2020.
  8. Tatar M, Keeshin SW, Mailliard M, Wilson FA (2020). Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. JAMA Netw Open, 3(9), e2015756.
  9. Jones TW, De la Cruz C, Spivak A, Keeshin SW (2019). The PrEP Care Continuum among an Uninsured Patient Population in Utah. Open Forum Infectious Diseases, 6(2), S458–S459.
  10. Parsons K, Cipriano SD, Rosen LB, Browne SK, Walter JE, Stone BL, Keeshin S, Chen K (2019). Severe Facial Herpes Vegetans and Viremia in NFKB2-Deficient Common Variable Immunodeficiency. Front Pediatr, 7, 61.
  11. Schwarz-Justin M, Keeshin SW (2018). Knowledge, Practices, and Attitudes of Youth Providers About STI, HIV Testing, and PrEP. Open Forum Infectious Disease, 5(1), S697.
  12. Keeshin SW, Feinberg J (2016). Text Message Reminder-Recall to Increase HPV Immunization in Young HIV-1-Infected Patients. J Int Assoc Provid AIDS Care, 16(2), 110-113.
  13. Keeshin SW, Feinberg J (2016). Endocarditis as a Marker for New Epidemics of Injection Drug Use. Am J Med Sci, 352(6), 609-614.
  14. Keeshin SW, Feinberg J (1/2015). Evaluation of dolutegravir safety for the treatment of HIV-1. Expert Opin Drug Saf, 14(1), 141-7.
  15. Barnette P, Scholl R, Blandford M, Ballard L, Tsodikov A, Magee J, Williams S, Robertson M, Ali-Osman F, Lemons R, Keller C (2004). High-throughput detection of glutathione s-transferase polymorphic alleles in a pediatric cancer population. Cancer Epidemiol Biomarkers Prev, 13(2), 304-13.
  16. Wang Y, Williams S, Ferris C (2003). Co-Induction of H0-1 and ATP-dependent iron transport by stressful stimuli. Gastroenterology, 124(4), A724-725.

Review

  1. Feinberg J, Keeshin S (2022). Prevention and Initial Management of HIV Infection. [Review]. Ann Intern Med, 175(6), ITC81-ITC96.
  2. Feinberg J, Keeshin S (2017). Management of Newly Diagnosed HIV Infection. [Review]. Ann Intern Med, 167(1), ITC1-ITC16.

Book Chapter

  1. Keeshin, SW (2025). Children and Youth Living With or Affected by HIV. In Fostering Health: Health Care for Children and Adolescents in Foster Care (3). American Academy of Pediatrics.
  2. Keeshin, S (2024). Injuries from Needles Discarded in the Community. In The Red Book 2024: Report of the Committee on Infectious Diseases (33). American Academy of Pediatrics.
  3. Hersh A, Keeshin S (2021). Injuries from Discarded Needles in the Community. In The Red Book 2021:The Report of the Committee of Infectious Diseases (32). American Academy of Pediatrics.

Abstract

  1. Garrett B, Spivak A, Keeshin S (2019). The Power of Sharing the Love: Creating a Free PrEP Clinic to Prevent HIV Infection [Abstract].
  2. Keeshin SW, Feinberg J (2015). Text Messaging Reminder Recall to Increase HPV Immunization Uptake in Young HIV-1 Infected Patients. [Abstract]. 8th IAS Conference on HIV Pathogens Treatment and Prevention.
  3. Keeshin SW, Feinberg J (2012). Endocarditis as a Sentinel Marker for New Epidemics of Injection Drug Use and Hepatitis C Virus Infection [Abstract]. National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care.
  4. Keeshin SW, Feinberg J (2012). Screening for HCV and HIV in Patients Diagnosed with Infective Endocarditis at an Academic Medical Center in Metropolitan Cincinnati 1999-2009 [Abstract]. HIV and Liver Disease Meeting.
  5. Keeshin SW, Feinberg J (2012). The Impact of Infectious Disease Consultation on Infective Endocarditis Outcomes at a Tertiary Care Teaching Hospital [Abstract]. American Society of Microbiology General Meeting.
  6. Williams S, Wang Y, Ferris C (2002). Heme Oxygenase-1 and Iron ATPase Induction in Mice and Human Lymphoblast Cells [Abstract]. Vanderbilt University.
  7. Koppanati BM, Williams S, Gustafson DR (2001). Androgen Receptor Gene Repeats and Indices of Obesity in Older Adults [poster also presented orally] [Abstract]. Endocrine Society's Annual Scientific Meeting.

Other

  1. Keeshin, SW (Spring 2022). Barriers to Access in HIV Care. (14(1), pp. 8-11). The American Academy of HIV Medicine.
  2. Working groups of the Office of AIDS Research Advisory Council (2020). Interim Guidance for COVID-19 and Persons with HIV. Rockville(MD): Department of Health and Human Services.
  3. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission (2019). Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Rockville(MD): Department of Health and Human Services.

Schedule Online